Design and Development of an in Vitro Assay for Evaluation of Solid Vaginal Dosage Forms
Jyoti Gupta, Jason Qihai Tao, Sanjay Garg, Raida Al-Kassas
DOI: 10.4236/pp.2011.24037   PDF    HTML     8,145 Downloads   16,684 Views   Citations


Vaginal dosage forms are seen as a viable option for empowering women to protect themselves from the risk of HIV transmission. Because of limited research in the field, there is a lack of suitable dissolution methods established for determination of drug release from vaginal formulations inside the vaginal tract. The main aim of this study was to develop a simple, reliable and reproducible in vitro release method for evaluation of solid vaginal dosage forms (VDFs) which was hoped to exhibit a close in vitro-in vivo correlation. Dapivirine, a drug being developed as a microbicide and a well established marketed anti fungal drug, Clotrimazole were used as model drugs. Two doses (0.5 mg and 1.25 mg) of Dapivirine were prepared as novel rapidly disintegrating, bioadhesive tablets. Clotrimazole 100 mg, prepared in house as conventional release tablets and commercially available Canesten (Clotrimazole tablet 100 mg) were used. The in vitro drug release testing of these tablets was carried out using a designed system which consisted of modified USP dissolution Apparatus II in conjunction with Enhancer cell (as sample holder) in 150 ml capacity flasks instead of the standard 900 ml flasks. The suitability of the system was investigated for variable parameters such as formulation types, drug concentration, stirring speeds, media volume and comparison of in house product with marketed product. The method was successfully optimized at a volume of 100 ml and a low speed of 25 rpm at pH 4 and was found sensitive enough to distinguish between formulations and evaluate products of different strengths. A linear drug release profile (R2 = 0.99) was obtained in case of Dapivirine, indicating that drug release is controlled by diffusion. The developed dissolution system has a potential to exhibit a good in vitro-in vivo correlation in addition to carrying out routine dissolution tests for solid VDFs.

Share and Cite:

J. Gupta, J. Tao, S. Garg and R. Al-Kassas, "Design and Development of an in Vitro Assay for Evaluation of Solid Vaginal Dosage Forms," Pharmacology & Pharmacy, Vol. 2 No. 4, 2011, pp. 289-298. doi: 10.4236/pp.2011.24037.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] J. Das Neves, “Vaginal drug delivery”. 2008, SciTopics.
[2] J. Robinson, W. Bologna, “Vaginal and reproductive system treatments using a bioadhesive polymer”. J Control Rel. Vol. 28, 1994, pp. 87-94.
[3] A. Gursoy, A. Bayhan, 2007) “Testing of drug release from bioadhesive vaginal tablets. Drug Dev Ind Pharm. Vol. 17, No. 18, 2007, pp. 2457-2475.
[4] European Pharmacopoeia 60: EDQM (2007).
[5] British Pharmacopoeia. London: Stationary Office; 2009.
[6] United States Pharmacopoeia and National Formulary, 2009.
[7] A. El-Kamel, M. Sokar, V. Naggar, “Bioadhesive controlled release metronidazole vaginal tablets”, Acta Pharm, Vol. 52, 2002, pp. 171-179.
[8] S. Garg, L. Jambu, K. Vermani, “Development of novel sustained release bioadhesive vaginal tablets of Povidone Iodine. Drug Dev Ind Pharm. Vol. 33, 2007, pp. 1340- 1349.
[9] F. Ahmad, M. Alam, Z. Khan, M. Khar, M. Ali, “Development and in vitro evaluation of an acid buffering bioadhesive vaginal gel for mixed infections”. Acta Pharm, Vol. 58, 2008, pp. 407-19.
[10] L. Wang, X. Tang, “A novel Ketoconazole bioadhesive tablet for vaginal delivery: Design, in vitro and in vivo evaluation”. Int J Pharm. Vol 350, No. (1-2). 2008, 181-187.
[11] C. Lee, Y. Chien, “Development and evaluation of mucoadhesive drug delivery system for dualcontrolled delivery of nonoxynol-9”. J Control Rel., Vol. 39, 1996, pp. 93-103.
[12] C. Valenta, C. Kast, I. Harich, “Development and in vitro evaluation of a mucoadhesive vaginal delivery system for progesterone”. J Control Rel. Vol. 77, No. 3, 2001, pp. 323-332.
[13] V. Kale, R. Trivedi, P. Muley, (2008) “Proposed Design of a Dissolution Apparatus for Vaginal Formulations Containing Probiotics”. Dissolution Technologies. Vol. 15, No. 2, 2008.
[14] P. Rege, V. Vilivalam, C. Collins, “Development in release testing of topical dosage forms: use of Enhancer cell with automated sampling”. J Pharm Biom Anal, Vol. 17, 1998, pp. 1225-1233.
[15] W. Liebenberg, E. Engelbrecht, A. Wessels, “(2004) A comparative study of the release of active ingredients from semisolid cosmeceuticals measured with Franz, Enhancer or Flow through cell diffusion apparatus. J Food Drug Anal. Vol. 12, No. 1, 2004, pp. 19-28.
[16] J. Nuttall, D. Thake, M. Lewis, (2008) “Concentrations of Dapivirine in the Rhesus Macaque and Rabbit following Once Daily Intravaginal Administration of a Gel Formulation of [14C] Dapivirine for 7 Days. Antimicrob Ag Chemother, Vol. 52, No. 3, 2008, pp. 909-914.
[17] K. Vermani, S. Garg S, (2000) The scope and potential of vaginal drug delivery. Pharm Sci Tech Today. Vol. 3, No. 10, 2000, pp. 359-364.
[18] D. Owen, D. Katz, “A vaginal fluid stimulant”. Contraceptives, Vol. 59, 1999, pp.91-95.
[19] A. Woolfson, R. Malcom, R. Morrow, “Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide”. Int J Pharm. Vol 325, No.1-2, 2006, 82-89.
[20] K. Gupta, S. Pearce, A. Poursaid, 2008) “Polyurethane Intravaginal Ring for controlled delivery of Dapivirine, a Nonnucleoside Reverse Transcriptase Inhibitor of HIV-1”. J Pharm Sci. Vol. 97, No. 10, 2008, pp. 4228-4239.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.